Analytical, physiologic, and clinical validation of a radioimmunoassay for measurement of procollagen tyoe III amino terminal propeptide in serum and bronchoalveolar lavage fluid obtained from dogs

American Journal of Veterinary Research

Volumn 67, Issue 5, 2006, Pages 749-755

  Schuller, Simone ^a,c   Valentin, Sphie ^a   Remy, Benoit ^a   Jespers, Pascale ^b   Foulon, Suzanne ^b   Van Israël, Nicole ^a   Clercx, Cécile ^a   McEntee, Kathleen ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

AGE; ANALYTIC METHOD; ARTICLE; BIRTH WEIGHT; BRONCHOPNEUMONIA; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOG DISEASE; FEMALE; HISTOPATHOLOGY; LUNG LAVAGE; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS; VALVULAR HEART DISEASE;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOPNEUMONIA; CARDIOMYOPATHIES; CHRONIC DISEASE; DOG DISEASES; DOGS; FEMALE; HEART VALVE DISEASES; KIDNEY FAILURE, CHRONIC; MALE; PEPTIDE FRAGMENTS; PROCOLLAGEN; RADIOIMMUNOASSAY; REPRODUCIBILITY OF RESULTS;

CANIS FAMILIARIS;

EID: 33744468773     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.5.749     Document Type: Article

References (38)

1. Bitterman PB, Henke CA. Fibroproliferative disorders. Chest 1991;99(suppl 3):81S-84S.
2. Risteli L, Risteli J. Analysis of extracellular matrix proteins in biological fluids. Methods Enzymol 1987;145:391-411.
3. Fessler JH, Fessler LI. Biosynthesis of procollagen. Annu Rev Biochem 1978;47:129-162.
4. Pierard D, Nusgens BV, Lapiere CM. Radioimmunoassay for the amino-terminal sequences of type III procollagen in human body fluids measuring fragmented precursor sequences. Anal Biochem 1984;141:127-136.
5. Low RB, Cutroneo KR, Davins GS, et al. Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest 1983;48:755-759.
6. Jensen LT. The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology. Dan Med Bull 1997;44:70-78.
7. Risteli L, Risteli J. Non-invasive methods for detection of organ fibrosis. In: Roijkind M, ed. Connective tissue in health and disease. Boca Raton, Fla: CRP Press, 1990;61-98.
8. Trivedi P, Cheeseman P, Portmann B, et al. Variation in serum type III procollagen peptide with age in healthy subjects and its comparative value in the assessment of disease activity in children and adults with chronic active hepatitis. Eur J Clin Invest 1985;15:69-74.
9. Risteli J, Niemi S, Trivedi P, et al. Rapid equilibrium radioimmunoassay for the amino-terminal propreptide of human type III procollagen. Clin Chem 1988;34:715-718.
10. Leroy V, Monier F, Bottari S, et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004;99:271-279.
11. Niemela O, Risteli J, Blake JE, et al. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990;98:1612-1619.
12. Hochweiss S, Fruchtman S, Hahn EG, et al. Increased serum procollagen III aminoterminal peptide in myelofibrosis. Am J Hematol 1983;15:343-351.
13. Lee YJ, Shin KC, Kang SW, et al. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis. Clin Exp Rheumatol 2001;19:69-74.
14. Zhu GG, Stenback F, Risteli L, et al. Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study. Cancer 1993;72:1679-1684.
15. Uusimaa P, Risteli J, Niemela M, et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997;96:2565-2572.
16. Klappacher G, Franzen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995;75:913-918.
17. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001;38:1227-1232.
18. Keller F, Rehbein C, Schwarz A, et al. Increased procollagen III production in patients with kidney disease. Nephron 1988; 50:332-337.
19. Honkanen E, Froseth B, Gronhagen-Riska C. Serum hyaluronic acid and procollagen III amino terminal propeptide in chronic renal failure. Am J Nephrol 1991;11:201-206.
20. Teppo AM, Tornroth T, Honkanen E, et al. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation 2003;75:2113-2119.
21. Entzian P, Huckstadt A, Kreipe H, et al. Determination of serum concentrations of type III procollagen peptide in mechanically-ventilated patients. Am Rev Respir Dis 1990;142:1079-1082.
22. Lammi L, Kinnula V, Lahde S, et al. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Eur Respir J 1997;10:2725-2730.
23. Clercx C, Peeters D, Snaps F, et al. Eosinophilic bronchopneumopathy in dogs. J Vet Intern Med 2000;14:282-291.
24. Jones S. Structure, biosynthesis and disorders of collagen: a review. Bull Am Soc Vet Clin Pathol 1976;5:4-16.
25. Jensen LT, Hendriksen JH, Risteli J, et al. Fate of circulating amino-terminal propeptide of type III procollagen in conscious pigs. Am J Physiol 1993;265:R139-R145.
26. Madsen JS, Svalastoga E, Jensen L. Serum concentration of procollagen type III aminoterminal peptide in growing dogs with hip dysplasia. Acta Vet Scand 1995;36:157-160.
27. Eto N, Yoshino J, Inui K, et al. Fluctuations of the fibrosis markers with aging. Nippon Ronen Igakkai Zasshi 2002;39:176-180.
28. Laron Z, Klinger B, Jensen LT, et al. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol (Oxf) 1991;35:145-150.
29. Sartorio A, Agosti F, Marazzi N, et al. Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report. Clin Endocrinol (Oxf) 2004;61:487-493.
30. Eigenmann JE, Amador A, Patterson DF. Insulin-like growth factor I levels in proportionate dogs, chondrodystrophic dogs and in giant dogs. Acta Endocrinol (Copenh) 1988;118:105-108.
31. Rasmussen MH, Jensen LY, Andersen T, et al. Collagen metabolism in obesity: the effect of weight loss. Int J Obes Relat Metab Disord 1995;19:659-663.
32. Risteli J, Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 1995;22(suppl 2):77-81.
33. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-262.
34. Brower GL, Janicki JS. Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol 2001;280:H674-H683.
35. Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation 1997;96:2488-2492.
36. Clercx C, Peeters D, German AJ, et al. An immunologic investigation of canine eosinophilic bronchopneumopathy. J Vet Intern Med 2002;16:229-237.
37. Rajamäki MM, Jarvinen AK, Sorsa T, et al. Collagenolytic activity in bronchoalveolar lavage fluid in canine pulmonary eosinophilia. J Vet Intern Med 2002;16:658-664.
38. Rajamäki MM, Jarvinen AK, Sorsa T, et al. Clinical findings, bronchoalveolar lavage fluid cytology and matrix metalloproteinase-2 and -9 in canine pulmonary eosinophilia. Vet J 2002;163:168-181.